Neuromodulation companies develop implanted and noninvasive devices that alter electrical activity in the brain, spinal cord, peripheral nerves and autonomic nervous system to treat neurological, psychiatric, pain-related, respiratory and cardiovascular disorders.
13 tickers·$391.88B market cap
10D-11.52%#1,414of 1,461 themes/1,461#14of 14 in MedTech/14 MedTech